FY2017 Earnings Forecast for Charles River Laboratories International, Inc. Issued By SunTrust Banks (CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at SunTrust Banks boosted their FY2017 EPS estimates for shares of Charles River Laboratories International in a report issued on Thursday. SunTrust Banks analyst S. Draper now expects that the medical research company will earn $5.15 per share for the year, up from their prior estimate of $5.10. SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock. SunTrust Banks also issued estimates for Charles River Laboratories International’s Q4 2017 earnings at $1.26 EPS and FY2019 earnings at $6.47 EPS.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The firm had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period last year, the business earned $1.18 earnings per share. Charles River Laboratories International’s revenue was up 9.0% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “FY2017 Earnings Forecast for Charles River Laboratories International, Inc. Issued By SunTrust Banks (CRL)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/19/fy2017-earnings-forecast-for-charles-river-laboratories-international-inc-issued-by-suntrust-banks-crl.html.

Several other research firms have also recently issued reports on CRL. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. ValuEngine cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Robert W. Baird restated a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research report on Friday, September 1st. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Finally, BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories International presently has an average rating of “Buy” and an average target price of $106.63.

Shares of Charles River Laboratories International (NYSE CRL) opened at $101.39 on Friday. Charles River Laboratories International has a 12-month low of $69.51 and a 12-month high of $119.05. The stock has a market cap of $4,802.03, a PE ratio of 19.92, a P/E/G ratio of 1.62 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. In the last three months, insiders bought 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. Company insiders own 2.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. YorkBridge Wealth Partners LLC boosted its stake in shares of Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Charles River Laboratories International by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 548 shares during the period. Advisor Group Inc. boosted its stake in shares of Charles River Laboratories International by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the period. Finally, Riverhead Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the period. 97.46% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply